Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2314
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2014
Authors
Publisher
Elsevier BV